This week on Sg2 Perspectives, podcast host Jayme Zage, PhD, is joined by Vizient Senior Principal, Pharmacy Solutions, Steven Lucio, PharmD, BCPS, and Sg2 Senior Director Katherine Zentner to talk about the emergence of new therapeutics in the management of Alzheimer disease, along with the challenges and the benefits that they bring. Steven and Kate discuss the new antibody therapy LEQEMBI and how it’s changing the finances around therapeutics, the impact of new Alzheimer disease therapeutics on neurosciences programs, and how providers can prepare themselves for future innovations in the neurosciences space.

We are always excited to get ideas and feedback from our listeners. You can reach us at [email protected], find us on Twitter as @Sg2HealthCare, or visit the Sg2 company page on LinkedIn.